Insulin-like growth factors

New England Journal of Medicine

Volumn 336, Issue 9, 1997, Pages 633-640

  Le Roith, Derek ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; INSULIN; INSULIN RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; SOMATOMEDIN C RECEPTOR;

ACROMEGALY; ASYSTOLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DYSPNEA; FACE EDEMA; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; LARON SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR BINDING; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH; CHEMISTRY; METABOLISM; PHYSIOLOGY; REVIEW;

HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RECEPTORS, SOMATOMEDIN;

EID: 0031587697     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199702273360907     Document Type: Conference Paper

References (41)

1. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68-91.
2. Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M. Clinical uses of insulin-like growth factor I. Ann Intern Med 1994;120:593-601.
3. Kolaczynski JW, Caro JF. Insulin-like growth fector-1 therapy in diabetes: physiologic basis, clinical benefits, and risks. Ann Intern Med 1994;120:47-55.
4. Clemmons DR, Underwood LE. Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994;79:4-6.
5. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995;16:3-34.
6. Kahn CR. The molecular mechanism of insulin action. Annu Rev Med 1985;36:429-51.
7. LeRoith D, Adamo M, Werner H, Roberts CT Jr. Insulin-like growth factors, and their receptors as growth regulators in normal physiology and pathological states. Trends Endocrinol Metab 1991;2:134-9.
8. Baker J, Liu J-P, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
9. Ruderman N, Moses AC, Moller DE. Insulin, insulin-like growth factors, and their receptors. In: Arias IM, ed. The liver: biology and pathobiology. 3rd ed. New York: Raven Press, 1994:969-96.
10. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995;16:143-63.
11. LeRoith D, Clemmons D, Nissley P, Rechler MM. Insulin-like growth factors in health and disease. Ann Intern Med 1992;116:854-62.
12. August GP. Growth and development in the normal infant and child. In: Becker KL, ed. Principles and practice of endocrinology and metabolism. Philadelphia: J.B. Lippincott, 1990:72-80.
13. Laron Z. Disorders of growth hormone resistance in childhood. Curr Opin Pediatr 1993;5:474-80.
14. Isley WL, Underwood LE, Clemmons DR. Dietary components that regulate serum somatomedin-C concentrations in humans. J Clin Invest 1983;71:175-82.
15. Hall K, Johansson BL, Povoa G, Thalme B. Serum levels of insulin-like growth factor (IGF) I, II and IGF binding protein in diabetic adolescents treated with continuous subcutaneous insulin infusion. J Intern Med 1989;225:273-8.
16. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-31.
17. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-9.
18. Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med 1988;319:1434-40.
19. Lowe WL Jr, Roberts CT Jr, LeRoith D, et al. Insulin-like growth factor-II in nonislet cell tumors associated with hypoglycemia: increased levels of messenger ribonucleic acid. J Clin Endocrinol Metab 1989;69:1153-9.
20. Eastman RC, Carson RE, Orloff DG, et al. Glucose utilization in a patient with hepatoma and hypoglycemia: assessment by a positron emission tomography. J Clin Invest 1992;89:1958-63.
21. Baxter RC, Daughaday WH. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab 1991;73:696-702.
22. Zapf J. Role of insulin-like growth factor (IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia. J Intern Med 1993;234:543-52.
23. Shalet SM, Rahim A, Toogood AA. Growth hormone therapy for adult growth hormone deficiency. Trends Endocrinol Metab 1996;7:287-90.
24. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992;339:1258-61.
25. Wilton P. Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome): Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatr Suppl 1992;383:137-42.
26. Backeljauw PF, Underwood LE, GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - a clinical research center study. J Clin Endocrinol Metab 1996;81:3312-7.
27. Taylor SI. Molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992;41:1473-90.
28. Schoenle EJ, Zenobi PD, Torresani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia 1991;34:675-9.
29. Quin JD, Fisher BM, Paterson KR, Inoue A, Beastall GH, MacCuish AC. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. N Engl J Med 1990;323:1425-6.
30. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS. Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 1995;28:Suppl: S185-S194.
31. Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993;42:696-705.
32. Dunger DB, Cheetham TD, Crowne EC. Insulin-like growth factors (IGFs) and IGF-I treatment in the adolescent with insulin-dependent diabetes mellitus. Metabolism 1995;44:Suppl 4:119-23.
33. Bach MA, Chin E, Bondy CA. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1994;79:1040-5.
34. Moller DE, Flier JS. Insulin resistance - mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-48.
35. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER. Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 1992;90:2234-41.
36. Moses AC, Young SCJ, Morrow LA, O'Brien M, Clemmons DR. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 1996;45:91-100.
37. Jabri N, Schalch DS, Schwartz SL, et al. Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients. Diabetes 1994;43:369-74.
38. RhIGF-I in NIDDM Study (RINDS) Group. Evidence from a dose-ranging study that recombinant insulin-like growth factor I (RhIGF-I) effectively and safely improves glycemic control in non-insulin dependent diabetes mellitus (NIDDM). Diabetes 1996;45:Suppl 2:27A. abstract.
39. Usala A-L, Madigan T, Burgucra B, et al. High dose intravenous, but not low dose subcutaneous, insulin-like growth factor-I therapy induces sustained insulin sensitivity in severely resistant type I diabetes mellitus. J Clin Endocrinol Metab 1994;79:435-40.
40. Malozowski S, Stadel B. Risks and benefits of insulin-like growth factor. Ann Intern Med 1994;121:549.
41. King GL, Goodman AD, Buzney S, Moses AC, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985;75:1028-36.